Metraipolis › archive › dc_7bf8027c210b
Systemic and gut microbiome changes with metformin and liraglutide in youth-onset type 2 diabetes: the MIGHTY study — Europe PMC PMID:41020378
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41020378
- DOI
- 10.1080/19490976.2025.2558071
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-08T01:43:27.252Z
- SHA-256 of the archived text
e4b609ef2b56d01af2b97deaf88eeaa409d246a3834bc10b30bec80c91a9cd5e- Stable URL of this page
https://metraipolis.com/documento/dc_7bf8027c210b
How to cite
Systemic and gut microbiome changes with metformin and liraglutide in youth-onset type 2 diabetes: the MIGHTY study — Europe PMC PMID:41020378 — Europe PMC (en), https://europepmc.org/article/MED/41020378 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_7bf8027c210b (Metraipolis archive dc_7bf8027c210b, sha256 e4b609ef2b56d01af2b97deaf88eeaa409d246a3834bc10b30bec80c91a9cd5e)
BibTeX
@misc{dc7bf8027c210b,
title = {Systemic and gut microbiome changes with metformin and liraglutide in youth-onset type 2 diabetes: the MIGHTY study — Europe PMC PMID:41020378},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41020378},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_7bf8027c210b; sha256 e4b609ef2b56d01af2b97deaf88eeaa409d246a3834bc10b30bec80c91a9cd5e},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/41020378. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Metformin (Met) and liraglutide (Lira) are preferred diabetes therapies that may improve glycemia by modulating the gut microbiome, but the mechanisms and pathways are unknown and few data exist in youth-onset type 2 diabetes (Y-T2D). In a 3-month parallel clinical trial in African American Y-T2D randomized to Met ( n = 14) or Met+Lira ( n = 11), we compared gut microbial composition and metabolomic profiles and determined the relationship of changes in microbial abundance with glycemia and plasma metabolites. After 3 months, Met was associated with greater relative abundance of Eubacterium and Eubacterium rectale and lower Bacteroides ovates ( p Bacteroides fragilis and lower Streptococcus thermophilus ( p 1.5-fold) plasma cholic secondary bile acids (sulfochenodeoxycholic acid, nutriacholic acid, alpha-muricholic acid, and C24 dihydroxy bile acid; p ≤ 0.002). The change in nutriacholic acid correlated with lower fasting glucose ( r = -0.7, p Clinical trials.gov identifier : NCT02960659. Tema degli esploratori: ricerca e scienza aperta (ricerca Europe PMC «preprint», solo open access). Pubblicazione: Gut microbes, 2025 (prima pubblicazione 2025-09-29). Identificativi: PMID 41020378 · PMCID PMC12482426 · DOI 10.1080/19490976.2025.2558071. Parole chiave degli autori: Bile acid; Diabetes; Metformin; Metabolomics; Microbiome; Short-chain Fatty Acid; Glucagon-like Peptide-1 Receptor Agonist; Youth-onset Type 2 Diabetes. Descrittori MeSH principali: Bacteria; Diabetes Mellitus, Type 2; Metformin; Hypoglycemic Agents; Gastrointestinal Microbiome; Liraglutide. Pagina: https://europepmc.org/article/MED/41020378 — https://doi.org/10.1080/19490976.2025.2558071. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-08T01:17:01.506Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.